Effect of lorcaserin on weight reduction in persons with obstructive sleep apnea (OSA): a combined subgroup analysis from three randomized, controlled clinical trials.
Ken FujiokaC PerdomoM MalhotraPublished in: Obesity science & practice (2019)
In this retrospective analysis, persons with OSA showed significant and meaningful weight loss, blood pressure and heart rate reductions in patients treated with lorcaserin versus placebo. Persons with OSA lost just as much weight as those without OSA. Health care providers can expect persons with OSA to lose weight by diet, exercise and the weight loss medication lorcaserin comparable with persons without OSA. Further prospective research is warranted to evaluate impact of weight loss on OSA and overall outcomes for patients.
Keyphrases
- weight loss
- obstructive sleep apnea
- positive airway pressure
- bariatric surgery
- heart rate
- blood pressure
- roux en y gastric bypass
- gastric bypass
- healthcare
- clinical trial
- sleep apnea
- physical activity
- glycemic control
- end stage renal disease
- phase iii
- heart rate variability
- double blind
- weight gain
- body mass index
- ejection fraction
- newly diagnosed
- open label
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- obese patients
- high intensity
- phase ii
- type diabetes
- study protocol
- skeletal muscle
- insulin resistance
- blood glucose